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Abstract: The epidermal growth factor receptor (EGFR) is historically the prototypical receptor
tyrosine kinase, being the first cloned and the first where the importance of ligand-induced dimer
activation was ascertained. However, many years of structure determination has shown that EGFR is
not completely understood. One challenge is that the many structure fragments stored at the PDB only
provide a partial view because full-length proteins are flexible entities and dynamics play a key role in
their functionality. Another challenge is the shortage of high-resolution data on functionally important
higher-order complexes. Still, the interest in the structure/function relationships of EGFR remains
unabated because of the crucial role played by oncogenic EGFR mutants in driving non-small cell
lung cancer (NSCLC). Despite targeted therapies against EGFR setting a milestone in the treatment
of this disease, ubiquitous drug resistance inevitably emerges after one year or so of treatment.
The magnitude of the challenge has inspired novel strategies. Among these, the combination of
multi-disciplinary experiments and molecular dynamic (MD) simulations have been pivotal in
revealing the basic nature of EGFR monomers, dimers and multimers, and the structure-function
relationships that underpin the mechanisms by which EGFR dysregulation contributes to the onset of
NSCLC and resistance to treatment.
Keywords: EGFR; lung cancer; receptor signaling; structure; MD simulations
1. Introduction
This review aims to discuss EGFR structure/function mechanisms drawn from high-resolution
experimental and theoretical results. The sources are mostly X-ray crystallography combined with
dynamical insights from atomistic MD simulations, but also include results from single molecule
experiments predicting structural-function relationships testable by MD simulations. Placed in the
context of structural results available for wild type and mutant EGFR, we also discuss mechanisms
leading to the onset of dysregulated cell growth in NSCLC and resistance to targeted therapies.
1.1. EGFR and Its Connection with Oncogenic Cell Growth
The discovery of EGFR lagged ~25 years behind that of its first cognate ligand, the epidermal
growth factor (EGF). EGF is a polypeptide isolated in the late 1950s from the mouse submaxillary
salivary gland that enhances epidermal growth and keratinization (reviewed in [1]). A single pass
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170 KDa transmembrane glycoprotein, the EGFR was the first cell surface receptor to be found to
exhibit tyrosine kinase activity [2]. EGFR (aka HER1/ErbB1) is also the founding member of the
human EGFR (HER) tyrosine kinase family (HER2/ErbB2/Neu, HER3/ErbB3, and HER4/ErbB4), four
receptors that are among the ~60 receptor tyrosine kinases in the human genome [3]. Evolved from one
receptor/ligand pair in nematode Caenorhabditis elegans through one receptor with multiple ligands in
Drosophila melanogaster [4,5], the human (and vertebrate) EGFR family detects signals from 13 cognate
polypeptide growth factor ligands. Of these, 7 EGFR-binding agonists—namely EGF, transforming
growth factor α (TGFα), amphiregulin (AREG), betacellulin (BTC), epigen (EPN), epiregulin (EPR)
and heparin-binding EGF-like growth factor (HB-EGF)—contain a characteristic EGF-like consensus
domain responsible for EGFR binding, which involves six spatially conserved cysteine residues that
form three intermolecular disulphide bonds [6,7]. All EGFR ligands are transcribed as transmembrane
precursor proteins and are subsequently cleaved at the plasma membrane by cell surface proteases in
order to release mature, active growth factors competent to bind EGFR (reviewed in [8]). Different
EGFR binders display high affinity (EGF, TGFα, BTC, and HB-EGF) or 10- to 100-fold lower affinity
(EREG, EPGN, and AREG) [6], and are capable of eliciting distinct extracellular conformations in
EGFR [9], and thereby different cellular responses (for a review, see e.g., [10]).
The discovery that the dysregulated activation of EGFR is fundamentally important in cell
transformation was made when the complete amino acid sequence encoding the human EGFR, which
was derived in 1984 from cDNA clones extracted from placental and A431 carcinoma cells [11], revealed
a high degree of homology with the v-erbB mRNA retroviral oncogene of the avian erythroblastosis
virus, which encodes a truncated homologue of the human EGFR [12]. These results highlighted the
importance of tyrosine phosphorylation and EGFR signalling in cancer biology. A substantial body
of subsequent work has since shown that EGFR is frequently hyperactivated in human cancers via
mutation and/or overexpression [13]. Of specific relevance in this review are the somatic mutations
of EGFR that are associated with the development of lung cancer. This cancer type is not only the
most common cause of cancer deaths worldwide in the past few decades (reviewed in [14]) (e.g.,
1.6 million related deaths worldwide were reported in 2012 [15]) but also displays a five-year survival
rate (~17.8%) much lower than that of other leading cancers [16]. Treatment has evolved from
surgery combined with cisplatin-based chemotherapy to the use of personalised targeted therapies.
This approach is exemplified in NSCLC, a group of histological diverse subtypes found in more than
80% of all lung cancer patients [14], in which tumour-driving EGFR mutations occur in approximately
10–20% of cases [17,18]. Mutant EGFR-driven NSCLC tumours are nowadays the best-studied
example of oncogenic addiction in lung cancer [19]. The era of targeted therapies begun in NSCLC
with the deployment of the first compounds designed to switch off specific signalling molecules,
with a strong focus on aberrant, constitutively active EGFR mutant moieties to arrest oncogenic
EGFR-dependent uncontrolled cell proliferation [17,18,20–22]. Subsequently, other gene alterations,
including anaplastic lymphoma kinase gene (ALK) rearrangements, c-ros oncogene 1 (ROS1) fusions
and B-Raf proto-oncogene (BRAF) mutations have similarly led to the development of additional
targeted therapeutics [23]. However, ubiquitous drug resistance inevitably emerges after one year or
so of treatment with targeted drugs.
Another avenue of intervention has been to target molecular chaperones, like the heat shock
protein HSP90 [24–26]. This chaperone has a fundamental role in regulating kinase activity, stabilizing
and promoting the multimerization of numerous kinases, including members of the EGFR family,
some of which (such as ErbB2) are obligatory clients of Hsp90 and are rapidly degraded upon its
inhibition [27]. What is more, the increased expression of Hsp90 allows cancer cells to tolerate adverse
environments and internal alterations deriving from accumulated mutations that would otherwise be
lethal [28,29].
1.2. A Brief Description of Methods to Derive EGFR Structural Properties
A number of methods have been employed to determine or infer the structure of EGFR, either
purified or within the cellular environment, to improve our understanding of the mechanisms driving
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drug resistance and to suggest the means to bypass it. The most commonly applied method for
rational drug design is x-ray crystallography. This method almost requires no introduction, given its
familiarity in structural biology, but in short, the protein of interest is first purified and then crystallized.
The crystal is then placed in an x-ray beam, produced either by an x-ray generator or a synchrotron,
and an electron density map determined from the measured intensities of the crystal’s diffraction
pattern. This brief description brushes over decades of development of this technique, across the areas
of protein crystallization, x-ray source and detector development, and data analysis methods. Those
wishing to read more of this story are referred to, for example, a recent methods compendium [30].
X-ray crystallography now regularly delivers protein structures with sub-Angstrom resolution and has
been hugely influential in biological research, including in studies of EGFR [31–37]. The reach of this
technique is demonstrated by the fact that, at the time of writing, the RCSB Protein Data Bank [38]
contains more than 133,000 protein structures determined using x-ray crystallography.
Despite the immense power of x-ray crystallography, it still by itself has not provided a universal
solution to the impinging questions of how changes in protein structure underpin drug efficacy
and resistance. One obvious consideration is that it requires proteins to be crystallised, and many
multi-domain or flexible proteins, like EGFR, have only proved to be amenable to crystallisation
fragment by fragment, in complex with exogenous binders, to stabilise a conformation, and devoid of
post-translational modifications. What is more, crystal contacts, expression tags and crystallisation
conditions might over-stabilize specific conformations or destabilise functionally-important states [39].
Often flexible regulatory regions are not visible. Methods are available that can be used to determine
protein structure and dynamics in solution. One of these is nuclear magnetic resonance spectroscopy
(NMR), in which the protein (either in solution or in the solid state) is placed in a strong magnetic
field and exposed to a radio frequency (RF) field. The absorption of RF by the nuclei of atoms in the
protein is sensitive to the environment of the atom, and reports on the presence of adjacent nuclei.
It is, therefore, possible to build up a map of distances between the nuclei, which can then be used
to determine the protein’s structure. Advanced NMR techniques are also able to reconstruct protein
dynamics across different time-scales and can be applied to molecules in solution or the solid state.
In solution NMR, spectral transitions are sharp, due to averaging of anisotropic NMR interactions.
Solid-state NMR (ssNMR) spectra are broader, as the full effects of anisotropic or orientation-dependent
interactions are observed in the spectrum. ssNMR methods are particularly applicable to membrane
proteins, because these proteins are immobilized in the lipid bilayer on the timescales of the chemical
shift and dipolar coupling spin interactions [40]. However, NMR also has a blind spot that makes
interesting regulatory regions invisible due to signal broadening. Again, NMR is a complex and highly
developed technique, and for more information, the reader is referred to the literature, e.g., [41].
Another method that can provide useful insights in the structure of uncrystallised proteins and
protein complexes is mass spectroscopy (MS), which measures the mass-to-charge ratio of ions to
identify and quantify molecules in simple and complex mixtures. In recent years it has developed
into an important tool for the study of protein structure, particularly with the introduction of methods
such as matrix-assisted laser desorption ionization (MALDI) and electrospray ionization (ESI) [42].
In the proteomics field, MS can, for example, provide information on protein complex topology,
protein folding, folding interactions and detect specific post-translational modifications in complex
biological mixtures.
Small angle X-ray solution scattering (SAXS) is another method that can provide protein structural
information albeit at low resolution. It works by measuring the intensity of elastically scattered x-rays
from protein molecules in solution. The scattering pattern provides information on the shape and size
of the protein being investigated. SAXS is often combined with atomic resolution structures to enable
modelling of protein complexes [43].
Lastly, transmission electron microscopy (TEM), and specifically single particle TEM under
cryogenic conditions is nowadays becoming the method of choice to investigate atomic resolution
protein structure in non-crystallised purified protein samples. In this technique, a solution of the
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protein is flash-frozen and imaged in the TEM in a thin layer of amorphous ice. Many (up to tens of
thousands) of images are recorded of individual protein molecules, across a wide range of orientations.
These are used to computationally reconstruct a model of the protein, at high resolution. Advances in
detector technology and analysis software mean that this technique can now deliver protein structures
at resolutions approaching that of x-ray crystallography [44].
The above techniques are currently used to resolve atomistic structures of isolated, purified
proteins either in crystalline form or in solution. However, in order to fully understand the protein’s
function in biological systems, it would be desirable to measure protein structure in the cell. Currently
no technique exists that can provide atomic resolution structure in cellulo, but a number of methods are
used to obtain lower-resolution structural information, which can be correlated with high-resolution
structure of purified proteins, and models from MD simulations, to provide a detailed structural
picture inside the cell (see for example [45]). One such method is Förster resonance energy transfer
(FRET), in which two protein types of interest are labelled with a fluorescent marker, one with the
so-called “donor”, and the other with an “acceptor”. The markers are chosen so that the fluorescence
emission spectrum of the donor overlaps the absorption spectrum of the acceptor. If the molecules are
close enough (< ~8 nm), on absorption of a photon the donor can transfer its energy non-radiatively to
a nearby acceptor. The efficiency of this FRET process varies with the 6th power of the separation of
the molecules, so provides a very precise (sub-nm) measurement of inter-molecular separation in the
sub-8 nm range [46]. The efficiency of FRET can be determined by measuring the fluorescence lifetime
of the donor molecule; this can be done in a microscope using a technique known as fluorescence
lifetime imaging microscopy (FLIM), allowing particular areas of the cell to be investigated [47].
FRET is a powerful technique for measuring relatively short intermolecular distances, but larger
complexes of molecules require a different approach. A method has been developed that makes use of
the principle of single-molecule localization, by which the location of a single fluorescence emitter can
be determined with nanometre precision [48]. The technique of fluorescence localization imaging with
photobleaching (FLImP) measures the shift in position of fluorescence from a pair of emitters when
one of the molecules photobleaches. This enables the distance between the molecules to be determined
in the range from ~5 nm to 60 nm. By accumulating many of these distance measurements it is
possible to determine the distribution of distances within protein complexes, providing, for example,
the proportion of dimers, trimers, and higher-order oligomers and their architecture on cells. FLImP
has been used to investigate EGFR oligomers in cells under a range of conditions [49,50].
No single structural technique described above is sufficient to fully characterize the structure and
organization of molecules in the cell. However, the combination of atomic resolution structures of
purified proteins and lower-resolution measurements of protein complexes in the cellular environment
is very powerful, particularly when the information is combined with modelling and MD simulations.
1.3. MD Simulation Methods Applied to EGFR Research
The MD simulation methodology, developed in the 60s, was first used to simulate the
dynamics of a small protein in 1977 [51] and has since become a suite of established techniques to
investigate structure-function relationships. As the available computer power increased exponentially,
MD simulations have grown in size (from a few hundred to millions of atoms) and length (from ps
to µs), thereby becoming a viable approach to study the conformational dynamics of many complex
biomolecular systems and their functional implication. MD simulations nowadays play a fundamental
role in understanding allosteric mechanisms like those underpinning EGFR signalling (reviewed
in [52]). Atomistic MD simulations are based on the integration of Newton’s equation of motion and a
simplified representation of the potential energy function, the force field. The most commonly used
biomolecular force fields, such as Amber, CHARMM and OPLS force-field families, build on Lifson’s
seminal work in the 60s, approximate the potential energy function by a combination of harmonic
springs for bond lengths and angles, a cosine expansion for dihedrals, Lennard-Jones potentials for
non-bonded interactions, and point charges and Coulomb’s law for electrostatic interactions (Lifson
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type force fields). Despite their simplified form, biomolecular force fields for water, proteins, glycans,
lipids, DNA and RNA, have been systematically refined and their most recent iterations (such as
Amber14, Amber-disp and CHARMM36m) are able to reproduce the structural, dynamical and
thermodynamical properties of very complex systems with surprising accuracy [53–60]. However,
the time-scales accessible to MD simulations are still limited by the small integration step used to
evolve Newton’s equations, which must be comparable to the characteristic timescales of the fastest
molecular motion (10−15 s for bonds vibration). Significant structural rearrangements, as the transitions
between different kinase conformations, take place in time scales of tens to hundreds of microseconds
and are difficult to observe in a typical MD simulation that, even using the fastest MD code on a
modern supercomputer might take a month to sample a few µs. Only recently, thanks to algorithmic
and hardware advancements, including supercomputers such as ‘Anton’ [61], a special-purpose
system for MD simulations using a large number of application-specific integrated circuits (ASICs),
MD codes running on GPUs and enhanced-sampling algorithms [62–66], the time-scales needed to
sample these phenomena have become accessible. Using Anton, it was possible to observe large
scale conformational changes in EGFR (e.g., [49,67]). But even on Anton, only one or a few reactive
events can be observed. To quantify the free energy and population differences between conformers,
allowing a direct comparison with experiments, a coarse-grained model or a more efficient sampling
approach is needed [68]. To this end, algorithms that combine a large number of trajectories, accelerate
rare events and compute the free energies can be used [62,64–66,68–71]. In the case of kinases, free
energy methods have been used to reconstruct the conformational free energy profile along a relevant
coordinate (collective variable or CV) that approximates the reaction coordinates [72,73]. However,
both the choice of a CV describing all relevant conformational changes and the convergence of the
reconstructed free energy profile are significant concerns [74] and may lead to a simplistic description
that is difficult to reconcile with the most up-to-date NMR evidence. A possible solution is to use
“CV-free” algorithms that enhance the sampling by using temperature, such as parallel tempering,
a modified Hamiltonian (as in Hamiltonian replica exchange) or combine many trajectories with
Markov state models [75]. CV algorithms can also be combined with multiple replica algorithms to
improve convergence, as in the case of parallel tempering metadynamics (PT-metaD) [76]. PT-metaD
was extensively and successfully used to calculate the conformational free energy landscape of the
catalytic domains of Abl (Abelson murine leukemia viral oncogene), Src, originally identified by
homology to the Rous sarcoma virus oncogene protein pp60 (v-src), fibroblast growth factor receptor
(FGFR), and P38 protein kinases, and validated by NMR, Hydrogen deuterium exchange (HDX)
mass spectrometry, and FRET experiments [39,77–79]. PT-metaD was also used to clarify the effect of
common oncogenic mutations on the conformational free energy landscape of the catalytic domains of
Abl, EGFR and BRAF [80–82].
2. The Glycosylated EGFR Monomer and Interactions with the Supporting Bilayer
The human EGFR gene encodes a 1210 amino acid sequence, in which the first 24 correspond
to a putative signal peptide. (The amino acid numbering used in this review does not count these).
EGFR has a single-pass transmembrane (TM) α-helical region (residues 618–44) embedded in the
plasma membrane that connects the N-terminal growth factor ligand-binding extracellular module
(ECM) (residues 1–617) to its associated intracellular module (ICM) (Figure 1a). The ICM is made of a
juxtamembrane (JM) domain (residues 645–677), composed of a N-terminal portion (JMA) (residues
645-663) and a C-terminal portion (JMB) (residues 664–677), a kinase domain (residues 678–954), and a
long and disordered carboxy-terminal tail region (residues 955–1186). This overall topology has been
conserved through evolution reflecting EGFR’s critical signalling role in cells and tissues
2.1. The Ligand-Binding ECMMonomer
The ECM of EGFR is made of four subdomains (DI-DIV), of which DI displays a similar topology to
DIII, and DII and DIV are cysteine-rich domains [31,83]. Its main functional role is to bind growth factor
molecules in the extracellular milieu. The main growth factor binding site is DIII. This was deciphered
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30 years ago in an elegant study in which various domains of the chicken EGFR were substituted by
domains of the human EGFR to generate chimeric chicken/human receptors [84]. Because the human
EGFR shows a ~100-fold higher binding affinity towards EGF, variations in the affinity of EGF for
different chimeric receptors identified DIII as a major EGF binding domain.
In the first published X-ray structure of the nearly complete solubilised monomeric ECM of
EGFR, often referred to as sEGFR, the ECM was weakly bound to EGF at DI with very low affinity
(at low pH) [85]. The data revealed a folded-over structure, so-called the tethered conformation,
in which a β-hairpin from DII forms an interaction with DIV (Figure 1b). This tethered conformation
was later found for the solubilised ECMs of two other members of the EGFR family (HER3
through SAXS and HER4 in a crystal [86,87]), for EGFR bound at DIII with the Fab fragment of
cetuximab/Erbitux/IMC-C225 [88] or a Nanobody/VHH domain (Figure 1c) [89]. Because the β-hairpin
of DII is the major dimerisation site previously revealed by ligand-bound dimer structures (discussed
later in Section 4.1), the tethered conformation was proposed to be an autoinhibitory mechanism
preventing the spontaneous formation of ligand-independent EGFR dimers (reviewed in [90]). However,
questioning this hypothesis, quantitative ligand-binding experiments on cells only found a limited role
for the DII-DIV tether in EGFR function (e.g., [87,90–92]).
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Figure 1. Topology, structure, and simulations of the epidermal growth factor receptor (EGFR) monomer.
(a) Cartoon of an EGFR monomer, showing its domain structure. (b) Ribbon representation of the
solubilised monomeric extracellular module (ECM) of EGFR (sEGFR) structure (Protein Data Bank
(PDB): 1NQL), showing the “tether”, in which an α-hairpin from DII forms an interaction with DIV.
Disulfide bonds are labelled in black (C1) and gray (C2). Taken, with permission, from Ferguson et al. [85].
(c) Ribbon representation of sEGFR with bound VHH domain 7D12 (PDB: 4KRL), again showing
the presence of the tether. Taken, with permission, from Schmitz et al. [89]]. (d) Extended monomer
structure of EGFR (PDB: 3NJP), taking a monomer unit from the ligand-bound back-to-back dimer.
The locations of glycosylated Asparagine residues are shown, one highlighted inside a grey box. Taken,
Cells 2019, 8, 316 7 of 33
with permission, from Irani [93]. (e) A molecular dynamic (MD) simulation of the sEGFR started
from the structure in d. The connecting point between the extracellular and the transmembrane
helices is marked by a circle. (f) As (e) but showing the near-complete receptor. Taken, with
permission, from Arkhipov et al. [67]. (g,h) Endpoint structures from 1 µs simulations of the (g)
nonglycosylated and (h) glycosylated EGFR in 1,2-dioleoylsn-glycero-3-phosphocholine (DOPC)/
sphingomyelin (SM)/cholesterol membranes. Subdomain DI shown in blue, DII in green, DIII in yellow
and DIV in red. The single-pass transmembrane (TM) domain is shown in orange, the intracellular
tyrosine kinase domain (TKD) in salmon, and the glycans in purple. Taken, with permission, from
Kaszuba et al. [94].
It is conceivable that receptors on the cell surface can sample a wider conformational landscape than
that reported by crystal structures because the latter originate from highly concentrated homogeneous
preparations of purified fragments. Indeed, recent ssNMR-based experiments on EGFR-rich A431 cell
membrane vesicles confirmed that the ligand-free state of the full-length EGFR monomer is highly
dynamic and that the ability to explore different conformations is of critical importance for EGFR
function [95] MD simulations can explore the wider conformational landscape at atomic resolution to
report conformational changes and alternative ECM conformations. For example, using Anton-based
technology Arkhipov et al. [67] carried out long-timescale atomistic simulations starting from the
tethered ECM monomer structure before and after removal of the bound EGF molecule [85]. The results
showed that, consistent with a limited role for the tether, DII and DIV disengaged in the scale of
microseconds, breaking the tether interaction. To explore further the conformational landscape,
Arkhipov et al. started from a subunit of the ligand-bound dimer structure in which monomer
ECMs adopt an extended conformation [96] (Figure 1d). The results again revealed a significant
conformational rearrangement after 1–5 µs, by which DIV bends around a ‘hinge’ (residues 502–514)
displacing the C-terminus of DIV towards the dimerisation arm of DII, the endpoint resembling a
compact hybrid between the starting extended conformation and the tethered conformation (Figure 1e).
The results of these simulations are consistent with a high degree of ECM monomer flexibility [95].
2.2. Glycosylation Regulates the Structure and Function of the ECM
Another difference between crystal structures and data from cells is that the ECM of cell surface
EGFR is heavily glycosylated with sugar moieties making up nearly 25% of the 180 KDa net mass of
the receptor. Glycosylation is fundamental to many receptor functions, such as ligand-independent
activation, growth factor binding affinity, and receptor dimerisation [97–99]. Glycosylation also
undergoes profound alterations in cancer, including in NSCLC [100–103].
A prevalent form is N-glycosylation, which is the covalent binding of sugar moieties to the
amide nitrogen atom of an asparagine [104]. Mass spectrometry, biochemical and activity assays, and
high-throughput methods are among the methods that have been used to investigate the glycosylation
sites of the full-length membrane-bound EGFR (see for example [105]). As shown in Figure 1d, results
revealed 10 Asparagines located within consensus N-glycosylation sequences (Asn-X-Ser/Thr, where X
can be any amino acid except proline [11]). These are Asn104, Asn151 in DI, Asn172 in DII, Asn328,
Asn337, Asn389, and Asn420 in DIII, and Asn504, Asn544, Asn579 and Asn599 in DIV. Of the 10
Asparagines, nine are glycosylated (i.e. all except Asn172) [106–109]. However, suggesting that the
consensus sequence is not necessary for N-glycosylation, a non-consensus asparagine, Asn32 in DI,
which forms part of an atypical glycosylation sequence (Asn-Asn-Cys), was also reported to be both
N-glycosylated and fucosylated (addition of fucose to the oligosaccharide glycan) [110].
The amino acid position of the sugar moieties reflects the breadth of different EGFR functions
regulated by glycosylation. For example, using a cell line expressing a point mutant of EGFR
(N579Q-EGFR), the glycosylation of Asn579, located in DIV at the tip of the tether loop with DII,
was shown to reinforce the tether interaction between these domains [111]. Crystal structures do
not typically include large chemical modifications, like glycosylation, because glycans are highly
flexible [104], and introduce microheterogeneity into the protein, both detrimental to crystal growth.
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Because of these challenges, MD simulations have played a key role in revealing the mechanisms by
which N-glycan moieties regulate EGFR structure. For example, Taylor et al. [105] deployed all-atom
MD simulations starting, like Arkhipov et al. [67], from a monomer subunit of the ligand-bound dimer
structure [31] to characterize the conformational preferences of the ECM in the presence and absence
of growth factor and N-glycosylation. The results show that the presence of ligand confers the major
conformational stability to EGFR and that this followed by N-glycosylation and lastly dimerisation,
which reveals the hierarchy of the structural variables determining the extracellular conformation
of EGFR.
Atomistic MD simulations were also performed by Irani et al. [112] to investigate how
N-glycosylation regulates ligand-binding affinity. The simulations showed that N-glycosylation
results in the formation of noncovalent interactions between glycans and amino acids nearby the EGF
binding site. Such interactions result in stronger electrostatic interactions between the growth factor
ligand and EGFR that stabilize the ligand-binding site, explaining the molecular mechanism by which
N-glycosylation regulates growth factor affinity.
2.3. Linking Across the Lipid Bilayer to the ICM
The flexibility of EGFR compounded with methodological limitations related to the crystallisation
of membrane proteins have so far prevented the crystallisation of the full-length receptor. Using Anton,
Arkhipov et al. [67] carried out a 5 µs-long simulation of the near-complete EGFR molecule embedded
in a lipid bilayer made of 1-Palmitoyl-2-oleoyl-SN-glycero-3-phosphocholine/phosphatidylserine
(POPC/POPS) (Figure 1f). The simulated unit included the ECM, the TM helix, the JMA segment, which
becomes embedded in the bilayer, the JMB portion, and the kinase domain in its inactive conformation
(discussed later in Section 3.2). The kinase domain was oriented relative to the bilayer to enable
contacts between the negatively charged membrane and two positively charged surface regions of the
kinase domain (Lys698, Lys690, Lys692 and Lys715, and Arg779, Arg817, Lys851 and Lys889). Because
the kinase domain was sequestered by the membrane, it was proposed that these ionic interactions
might contribute to the autoinhibition of the kinase active state because the membrane would occlude
the substrate-binding site of the kinase [67].
The relaxed ECM monomer established a large interfacial contact with the supporting lipid
bilayer, which predicts a very short separation between its N-terminus and the outer leaflet of the
membrane. This seemed inconsistent with the larger distances reported from FRET measurements of
glycosylated intact receptors on cells [113–115]. To address this, Kaszuba et al. [94] considered whether
the differences could be attributed to N-glycosylation by simulating a near-full-length glycosylated
receptor (residues 2–994). Atomistic MD simulations were carried out on both the nonglycosylated
receptor and after attaching to the ECM in silico universal N-glycan core Man3GlcNAc2 residues at
positions Asn151 (DI), Asn172 (DII) and Asn389 together with Asn420 (DIII) (Figure 1g,h). Instead of
the binary lipid chain used by Arkhipov et al. [67], the reconstructed chain was embedded in a ternary
lipid bilayer (1,2-dioleoylsn-glycero-3-phosphocholine (DOPC)/ sphingomyelin (SM)/Cholesterol)
designed to mimic a real mammalian plasma membrane. Earlier experimental work in EGFR
proteoliposomes show this lipid composition to be critical to prevent ligand-independent kinase
activation [116]. The results from these simulations, which covered ~1 µs, revealed that the presence of
the Man3GlcNAc2 glycan residues significantly altered the relative arrangement of individual domains
of the ECM and their alignment on the membrane. The N-glycosylated sites were found to act as
‘molecular cushions’ lifting DI and DIII from the membrane so that DIII no longer made contact with
the membrane [94].
3. Kinase Domain Conformations and Their Coupling to Tyrosine Kinase Inhibitors (TKIs)
3.1. Topology of the Catalytic Kinase Domain
Protein kinase domains are found in 2% of eukaryotic genes. Their function is to catalyse the
transfer of a γ-phosphate (PO43−) of adenosine triphosphate (ATP) to the hydroxyl-group of a tyrosine
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in the target substrate, a posttranslational modification that emerged more than a billion years ago
in single-cell organisms [117]. Because of the critical importance of tyrosine phosphorylation to
intracellular communication [3,118], tyrosine kinase structure is extremely well conserved [119]. Kinase
domains consist of a smaller N-lobe and a larger C-lobe [120] (Figure 2a). The N-lobe mostly comprises
five beta sheet strands (β1−β5) and a conserved alpha helix (αC) (residues 729–744). The C-lobe is
mostly composed of five alpha helices (αE, αF, αG, αH, αI). The ATP-binding site is within a deep
cleft sandwiched between the N-lobe and C-lobe and underneath a highly conserved glycine-rich
phosphate-binding loop, which connects β1 and β2 in the N-lobe. The glycine-rich loop coordinates
closely with the phosphates of ATP via backbone interactions [121]. The αC helix contains an absolutely
conserved glutamate (Glu738 in EGFR), which in the active state establishes an ion pair with a conserved
lysine residue in β3 (Lys721 in EGFR) coordinating the α and β phosphates of ATP (Figure 2b). The
C-lobe borders the ATP-binding cleft from below, contributing a highly conserved catalytic loop
(Asp812-Asn818 in EGFR), within which Asp812 interacts with the attacking hydroxyl site chain of the
tyrosine substrate, while Asn818 forms hydrogen bond interactions that orient Asp812. The C-lobe
also contributes the key regulatory activation loop (A-loop) (Asp831-Val852 in EGFR), which contains
at its base a conserved Asp-Phe-Gly (DFG) motif (Asp831-Gly833 in EGFR).
The C-terminal tail is EGFR’s autocatalytic substrate (Figure 1a). It binds the kinase in an
extended conformation across the front end of the ATP binding pocket close to the γ-phosphate of
the nucleotide [122]. Interactions between the kinase and its substrate are supported by the overall
conformation of the A-loop, including a β9 strand platform. The auto-catalytic activity of EGFR
results in the phosphorylation of main tyrosine residues along its C-terminal domain (Tyr974, Tyr992,
Tyr1048, Tyr1068, Tyr1086, Tyr1101 and Tyr1173) [123]). C-terminal tail phosphotyrosines serve as
docking sites for the recruitment of signalling proteins and adaptors containing Src homology 2
(SH2) and phosphotyrosine-binding (PTB) domains [4]. Tyrosine phosphorylation is immediately
responsible for the downstream signalling pathways engaged by EGFR via this fashion, namely the
RAS-RAF-MEK-ERK pathway and the PI3K-AKT-mTOR pathway, promoting cell proliferation and
cell survival, respectively [124].
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Figure 2. Structure and dynamics of the kinase domain. (a) Structure of the EGFR kinase domain
with the inhibitor erlotinib bound in the cleft between the amino-terminal and carboxy-terminal lobes
(PDB: 1M14). Taken, with permission, from Stamos et al. [120]. (b) The inhibitor binding site and
nearby residues from the EGFR kinase domain complexed with erlotinib. The dashed line indicates an
H-bond from the receptor to the drug, and a water molecule is shown as a pale blue sphere. Taken, with
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permission, from Stamos et al. [120]. (c) Structures of the EGFR binding site with three different
inhibitors bound; 1XKK (Lapatinib) [125], 2ITY (gefitinib) [126], 4HJO (erlotinib) [127]. (d) Structure of
Abelson murine leukemia viral oncogene homolog 1 (ABL) kinase domain complexed with the type II
inhibitor imatinib, showing the DFG-out conformation [128]. Both panels were taken, with permission,
from Treiber and Shah [129]. (e) Structure of ABL kinase domain complexed with the type I inhibitor
VX-680, showing the DFG-in conformation [130]. (f) MD simulations of the EGFR kinase monomer in
the time scale of 25 µs showing transitions between the active state and both the Src-like inactive and
the DFG-out inactive states of EGFR kinase. (g) Comparison of the extended conformation (blue) with
the initial active conformation (red). (h) Close-up of the hinge region, with and without hinge cracking
(blue and red, respectively). (f–h) taken, with permission, from Shan et al. [131].
3.2. TKIs Bind the ATP-Binding Kinase Pocket and Stabilise Active and Inactive Conformations
TKIs, as those shown bound to EGFR and ABL tyrosine kinases in Figure 2a–e, are small
ATP-mimetic molecules that block phosphorylation by competing with ATP [132]. TKI binding is
facilitated by the structural flexibility displayed by the glycine-rich loop in the absence of ATP [133]
(Figure 2a). To date, seven EGFR family-targeted TKIs have been FDA-approved [134], including
gefitinib (IressaTM) and erlotinib (TarcevaTM), neratinib (NerlynxTM), afatinib (GilotrifTM), lapatinib
(TykerbTM) and osimertinib (TagrissoTM) and two multi-kinase (including EGFR) targeting drugs
brigatinib (AlunbrigTM) and vandetanib (CaprelsaTM). TKIs have played a critical role in the fight
against NSCLC by harbouring activating mutations in the EGFR kinase. Recent developments in
multi-targeted drug discovery have also produced multi-targeted TKIs such as foretinib, which can
target both c-Met and AXL [135], two of the main bypass pathways of EGFR. Combination therapy
with trastuzumab [136], with the insulin-like growth factor receptor 1 (IGF1R) TKI linsitinib [137] or
with the anti-HER3 antibodies currently in development [138] can also prove beneficial to shut down
compensatory signalling. Other new therapies instead reverse the immune tolerance towards cancer
through the blockade of negative immune regulators such as PD-1/PD-1L and CTLA4 have enjoyed
vast success in clinical trials of NSCLC and bypass the need of targeting EGFR specifically, providing
an attractive therapeutic [139,140].
TKIs are classified according to the structure of their drug-enzyme complexes (reviewed in [141]).
The observed differences between type I and type II binding modes is often due to the para-substitution
on the aniline ring (Figure 2c). Type I usually carry a leading halogen whereas type II bear a bulky group
(a benzyl ring) [125]. Consequently, type I inhibitors bind the ATP pocket but do not penetrate the
allosteric pocket. Type II create an additional cavity deep into the ATP-binding cleft to accommodate
their leading benzyl ring. This cavity requires a large distortion in the glycine-rich loop achieved
by interactions between the benzyl ring of the TKI and a conserved aromatic residue [142]. In many
tyrosine kinases, contacts between type II inhibitors with the adjacent allosteric site are facilitated by
a kinase conformation in which the DFG motif at the N-terminus of the A-loop flips away from the
catalytic centre (DFG-out conformation) (Figure 2d).
TKIs are also classified according to their mode of binding [143–145]. The first generation binds
reversibly to the target enzyme and interrupt signalling by outcompeting ATP [146]. The second
generation integrates as a reactive warhead moiety the acrylamide fragment that alkylates a conserved
cysteine residue in the kinase domain (Cys773) [147], thereby establishing an irreversible bond. The
third and fourth generations are allosteric, EGFR mutant-specific and designed to overcome resistance
to TKIs in NSCLC (discussed further below in Section 3.3).
TKI binding stabilises different conformations of the kinase domain and this effect has been
exploited to facilitate crystallisation. Indeed, the first structures of EGFR’s kinase domain revealed by
X-ray crystallography were stabilised in an active conformation via the binding of a first generation
type I TKI [120] (Figure 2a). The data showed structural features characteristic of the kinase active
conformation [133]. These include: (i) the αC-helix is closely packed against the body of the N-lobe
(αC-in), thereby orienting Glu738 with respect to Lys721 to form the catalytically important salt bridge
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that couples the conformation of the αC-helix to nucleotide binding (Figure 2b); (ii) the DFG motif is in
contact with the catalytic site (DFG-in) (Figure 2d), thus underpinning ATP coordination; and (iii) the
A-loop is opened and arranged to bind substrate (Figure 2a).
In turn, the first structure revealing an inactive EGFR kinase conformation was bound to the
first generation TKI lapatinib [125]. Typical of inactive kinases, this structure displayed an ‘αC-out’
conformation (Figure 2d), in which the αC-helix is displaced outwards swinging out the conserved
Glu738, thus breaking the salt bridge with Lys721, and the A-loop is collapsed against the catalytic
site, thus occluding both nucleotide and substrate binding. However, the DFG motif pointed towards
the ATP-binding site, thus displaying a DFG-in conformation (Figure 2e). At the time, the finding
of the DGF-in conformation in the presence of lapatinib was unexpected, given that the ability to
adopt the DFG-out conformation contributes to the increased selectivity of type II inhibitors versus
type I [148]. For this reason, lapatinib is sometimes classified as a type I 12 inhibitor [141]. In the
DFG-in conformation, residues L834 to D838 of the A-loop, which form the β9 strand in the active
conformation, also form a two-turn helical segment that packs against the shifted αC helix. Since
the inactive conformation of EGFR’s kinase resembles the inactive conformations of Src and CDK2
kinases [126], it is often referred to as the “Src/CDK2-like inactive”. The DGF-out conformation was
later found for EGFR’s kinase domain, for example, in the crystal structure of the complex between the
EGFR kinase domain displaying the inactivating V924R mutation and an inhibitory mitogen-inducible
gene 6 (MIG6) peptide [37], a negative regulator of EGF receptor-mediated skin morphogenesis and
tumour formation, also known as RALT or Gene 33 [149].
Almost 60 PDB entries of EGFR kinase structures are nowadays available (reviewed in [150]). The
analysis of this ‘experimental ensemble’ reveals the clusters of active and inactive conformers that
dominate the wild type kinase native state. An unusual feature of EGFR’s kinase is that the structural
coupling between the αC helix and the A-loop [133], which is essential for the adoption of the active
kinase conformation, does not depend on the phosphorylation of the A-loop. In EGFR kinase this
position is occupied by the highly conserved, functionally important Tyr845. In many other tyrosine
kinases, e.g., the insulin receptor [3], a tyrosine in an equivalent position would stabilise the A-loop in
the inactive conformation and would need to be trans-phosphorylated by a partner kinase to release
the cis-autoinhibitory interactions and relax into an active conformation.
3.3. NSCLC Oncogenic Mutations and Their Impact on Structure and TKI Interactions
Common somatic mutations relevant to NSCLC are located within EGFR exons 18-21, which
encode a critical portion of the kinase domain [151], the most frequent is located in the A-loop (L834R).
L834R-EGFR displays sensitivity to first generation TKIs [134], but the development of a dominant
secondary amino acid substitution at Thr766 confers resistance to TKIs and unavoidably limits the
long-term efficiency of these drugs [152]. The T766M mutation is located in β5 of the N-lobe, in the
so-called ‘gatekeeper’ position because it controls the access of TKIs to a deep hydrophobic pocket
in the ATP binding site [153]. Given that the gatekeeper residue can regulate the ‘in’ versus ‘out’
conformations of the conserved DFG motif, the resistance to TKIs conferred by the T766M mutation
was first predicted to be due to a steric clash between the larger substituting methionine amino acid
on the gatekeeper side chain of T766M and the aniline moiety of first generation TKIs. This is the
so-called ‘gatekeeper’ hypothesis [153]. However, Yun et al. [154] showed that the Met766 residue can
shift to accommodate inhibitor binding, and proposed instead that resistance can be accounted for
by the greatly increased ATP-binding affinity (~8-fold) for T766M-EGFR, results later validated by
Yoshikawa et al. and Red-Brewer et al. [155,156].
The key role in resistance to TKIs of the secondary T766M mutation has focused investigations into
the development of inhibitors that target this mutant kinase. Partial sensitivity is maintained
with type II irreversible inhibitors like neratinib or afatinib [157]. However, the unrestrained
potency of type II irreversible TKIs against wild type EGFR results in severe epithelium-based
toxicity, reducing to impracticable levels the doses of drug that can be safely administered [158].
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Secondary resistance to type II irreversible inhibitors acquired through T766M can be countered
with mutant-selective third generation TKIs, such as osimertinib (AZD9291) [152]. Used in clinic,
osimertinib is a monoanilinopyrimidine compound that incorporates a Michael acceptor group that
forms a covalent bond with Cys773 located at the edge of the ATP-binding pocket. By binding
irreversibly, this inhibitor overcomes the increased ATP affinity of the T766M-EGFR mutant, while
largely sparing wild-type EGFR, thereby minimizing unwanted side effects at doses required for
meaningful therapeutic intervention (20–240 mg) [159]. Unfortunately, the efficacy of osimertinib
follows an identical pattern of activity followed by resistance as its predecessors, which occurs either
through loss of primary and secondary EGFR mutations or through the acquisition of tertiary mutations
(e.g., C773S) blocking the formation of the potency-conferring covalent bond [160].
Oncogenic and other mutations in the EGFR kinase region impact the conformational free-energy
landscape [80] and dynamics of the enzyme [161], adding to the differential enrichment of each
conformer population by allowing the kinase to sample additional conformations. From these
structural fingerprints underpinning enzyme dysregulation and resistance to TKIs can be ascertained.
All-atom MD simulations have provided a complementary view on how conformational intermediates
underpin enzymatic function and inhibitor binding. Using Anton, it was possible to perform a multiple
µs-long MD simulations to study the conformational “flip” of the conserved DFG motif in the ABL
kinase between the ‘in’ and ‘out’ states [162]. This “flip” is relevant as it is common with type II
inhibitors and is believed to play a role in the selectivity of imatinib, the first kinase inhibitor to be
used in targeted anticancer therapy. In their study, the authors identified a new, potentially druggable
state, and highlighted the role of DFG aspartate protonation in favouring different conformations.
However, evidence from crystal structures of wild type EGFR [127,163], L834R and L834R/T766M
mutant EGFR [161] have also suggested that sensitivity and resistance to TKIs is most likely due
to a complex interplay of protein conformational dynamics, competition from ATP, and state of
phosphorylation, rather than to the conformational specificity of the inhibitors per se.
Long MD simulations were also used to study the binding of the inhibitor lapatinib to EGFR [164],
which led the authors to postulate the existence of a hitherto unknown conformation of the αC-helix
from discrepancies in the calculated rate of association. The authors proposed that the slower binding
rate of lapatinib was due to the existence of a previously unknown conformation assumed by the
αC-helix, different from the “out” inactive conformation that binds lapatinib, and which the protein
must assume in order for the drug to bind. What is more, they proposed a new explanation for the
mode of action of the widespread mutation L834R, affecting the dimerization dynamics of EGFR despite
being distant from the dimerization interface (discussed further in Section 4.2). Their simulations are
consistent with a stabilization of the αC-helix “in” conformation by the mutation, which suppresses
the disorder of the helix and stabilizes the dimer.
Sutto et al. further investigated the effects of oncogenic mutations (L834R and T766M) on the
conformational free-energy landscape of the EGFR kinase domain through extensive MD simulations,
parallel tempering and metadynamics [80]. The conformational free-energy landscapes reconstructed
by the simulations show that, while the wild type EGFR mostly exists in the inactive conformation in
which the A-loop partially blocks the access to the catalytic cleft, the oncogenic mutants destabilize the
inactive conformation in favour of the active conformation. What is more, the mode of action of the two
mutations differ in interesting ways. The L834R mutation not only stabilizes the active conformation of
the A-loop at the expense of the inactive conformation but also rigidifies the αC-helix that is involved in
the dimerization interface, reconciling previously contrasting views [126,164]. The T766M “gatekeeper”
mutant favors activation of the A-loop by stabilizing a hydrophobic cluster, explaining the increased
affinity for ATP. However, it also leads to a less ordered dimerization interface, possibly destabilizing
the dimer. What is more, the combination of T766M with L834R shows a positive epistatic interaction.
Using Anton, Shan et al. [164] reported unbiased atomistic simulations of the EGFR kinase
monomer in the time scale of 25 µs showing transitions between the active state and both the Src-like
inactive and the DFG-out inactive states of EGFR kinase. These simulations identified a locally
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disordered intermediate state with characteristics of both the active and inactive states, in which the
αC-helix is partially disordered and adopts the αC-out inactive conformation, while the A-loop remains
in an active conformation and displaying a β9 strand (Figure 2f). The spontaneous transition from the
active to the so-called “Src-like inactive” conformation of the wild type kinase funnelled across two
different pathways, as also observed by Li et al. [165], who combined targeted MD, unbiased MD and
Bayesian clustering. In 60 µs long all-atom MD simulations, Shan et al. [131] revealed that the same
local disordered state appeared as an intermediate in transitions between the active state, the DFG-in,
Src-like inactive, and DFG-out inactive states of the EGFR kinase. Intermediate conformations were
accompanied by unfolding (or ‘cracking’) at the hinge region between the N-lobe and C-lobe, together
with the extraordinary conformational flexibility of the A-loop (Figure 2g), which highlights the overall
key role played in by the latter in the conformational dynamics of tyrosine kinases.
Shukla et al. [166] investigated key structural intermediates along the transition path between
the active and inactive states. Using Markov state models to explore the conformational landscape of
the c-src tyrosine kinase, potentially druggable allosteric sites in the intermediates were identified.
Allosteric inhibitors (so-called 4th generation inhibitors) are a new type of mutant-selective drug and
were identified in a screen of ~2.5 million compounds against purified L834R/T766M kinase [143].
Crystal structures revealed that the compounds bind an allosteric site created by the displacement of the
regulatory αC-helix in an inactive conformation of the kinase [143]. The affinity for the double mutant
kinase was in the low nM range and for the wild type kinase >50 µM. The findings suggested that, in
combination with anti-EGFR antibodies such as cetuximab, 4th generation inhibitors could overcome
resistance to the triple L834R/T766M/C773 mutation, which is resistant to all current EGFR-targeted
therapies. Recent MD simulations have investigated the structural basis underlying the binding of 4th
generation inhibitors [167]. The results revealed that the conformational destabilization of the short
helix that carries Leu834 in the wild type exposes the allosteric pocket, which is otherwise occluded by
a set of sidechains including L834.
The effect of mutations in the N-lobe of the kinase were investigated by Paladino et al. [168]
who used a novel computational scheme based on the analysis of internal protein energetics and
flexibility/rigidity to describe protein dynamics in order to analyse the active and inactive forms of the
kinase domain of EGFR in the presence and absence of the G695S mutation. Suggesting a mechanism
by which N-lobe mutations favours the active state, energy decomposition analysis of the EGFR kinase
incorporating the G695S mutation and in the active conformation showed a remarkable increase in the
contribution of the N-lobe residues to the stability of the kinase domain. This was still present but was
somewhat less prominent in the inactive state [168,169].
4. Regulation of EGFR Enzymatic Activation by Ligand-Induced Dimerisation
4.1. The Stable Heart-Shape of the Ligand-Bound Extracellular Dimer Module
Ligand binding to the ECM of EGFR promotes the formation of a dimeric receptor (Figure 3a).
Our understanding of the ligand-bound structure of the extracellular portion of dimeric human EGFR is
based on three X-ray crystal structures. The two structures first published in 2002 show a ligand-bound
dimer lacking almost the entire DIV and bound to two ligands [31,83]. This structure denominated the
back-to-back dimer because dimerisation was almost exclusively mediated by a β-hairpin of DII of the
ECM, or the dimerisation arm. A more recent structure of the back-to-back dimer [96] includes a clear
density in the parts of DIV missing in the previous two (Figure 3a), identifying a small C-terminal
DIV dimerisation interface which gives the ligand-bound dimer structure the heart-shape appearance
recapitulated by electron microscopy studies [171]. Comparison between the tethered monomer and
the extended back-to-back dimer reveals the ∼130◦ conformational rotation of DI and DII with respect
to DIII and DIV that would be induced by ligand-binding to transition between the two structures.
Notably, the rotating domains (DI and DII), which are rigid β-helix/solenoid structures, would not
change conformation during the rotation. The putative orientation of DIV with respect to the membrane
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assumed in the cartoon of Figure 3a would also be largely maintained [85,169]. Ligand-binding would
induce a different conformational transition upon binding the ECM suggested by MD simulations
(Figure 1f). Reminiscent of the extension of a swinging arm, DI, DII and DIII would rotate clockwise
around its hinge with DIV while DIV rotates anticlockwise, thus arriving at the extended conformation
observed in the back-to-back dimer structure.
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Figure 3. The ligan - ce lular back-to-back dimer. (a) A model of ligand-induced EGFR
dimerization. tr sition is shown betw en the monomer tethered str cture on the left (model
derived fro [85]) and the active i er o t e right (model derived from [31]). The “back-to-back”
dimer includes the DIV modules missing from earlier structures. Taken, with permission, from Burgess
et al. [170]. (b) Simulation of the effects of removal of the ligand, showing a significant rearrangement
by which the gap between DI and DIII left by the detached ligand is filled, and a bending motion of DIV
around the hinge region with DIII leads to a separation between the C-terminal portions of DIV. Taken,
with permission, from Arkhipov et al. [67]. (c) A simulation showing the fully glycosylated ectodomain
dimer. The glycans are coloured by atom type (carbon in grey, oxygen in red and nitrogen in blue).
The conformation after 3 µs of simulation is shown on the right, from two opposing viewpoints. Taken,
with permission, from Arkhipov et al. [45].
Unlike the results from the MD simulations of the monomer ECM, for which the tethered structure
conformation was unstable during MD simulations, Arkhipov et al. [67] showed that the heart-shape
dimer conformation of the extended two-liganded dimer remained stable. To investigate the effect of
the bound-ligand, one and both ligands were removed from the back-to-back structure (Figure 3b).
The one-liganded back-to-back conformation is not stable but becomes so when both ligands are
removed. The results showed a significant rearrangement; specifically, the gap between DI and DIII
left by the detached ligand was filled, both domains coming into contact with each other. There is also
a rearrangement of DI and DIII resulting in a bending motion of DIV around the hinge region with DIII
leading to an increased separation between the C-terminal portions of the two DIVs. The latter proved
to be crucial in providing an understanding of the type of link across the membrane established by
these ligand-free inactive complexes (discussed further in Section 4.5).
In subsequent work, Arkhipov et al. [45] performed MD simulations of the ECM dimer in which
each monomer was glycosylated in 10 of the 12 potential Asn sites using three types of glycans (BiS1F1,
Man6 and Man8) (Figure 3c). One of the aims was to investigate whether glycosylation could provide
any structural basis to the unexplained negative cooperativity in the ligand binding ubiquitously
observed for full-length EGFR on cells (see for example [172]). In the context of a monomer-dimer
transition, the negative cooperativity of ligand-binding reveals that when one ligand-binding site
of EGFR dimer is occupied, the binding of the second ligand takes place with lower affinity [172].
This phenomenon was structurally explained for the EGFR dimer of labelled D. melanogaster by the
two structurally distinct ligand-binding sites observed in the crystal structure [173], but cannot be
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explained by the structure of the human back-to-back EGFR dimer, which displays two virtually
identical ligand-binding sites [31,83]. Arkhipov et al. showed that negative cooperativity could not
be accounted for by glycosylation. However, simulations suggested that one of the EGF molecules
bound to the dimer may occasionally rest on the membrane, an event found to be independent of
glycosylation, and that the interaction between the EGF ligand and the membrane may lead to a
breaking of the symmetry between the two ligands, thus contributing to the negative cooperativity of
EGFR ligand binding. We will return to the subject of negative cooperativity in Section 5 in the context
of higher order oligomers.
4.2. Active Kinase Dimers and Structural Cross-Talk Across the Asymmetric Interface
For the kinase domain of EGFR to become catalytically active in response to ligand binding,
ligand-induced dimerisation must be transduced across the plasma membrane. In a seminal work,
Kuriyan and co-workers unravelled the structural details of how dimerisation underpins kinase
activation [36] (Figure 4). They discovered that two EGFR kinase domains interact in an asymmetric
fashion by which the C-lobe of the ‘activator’ contacts the N-lobe of the ‘receiver’ at points of the
αC-helix, the β4/β5 loop and an N-terminal extension of the N-lobe (Figure 4a). Formation of this
asymmetric kinase dimer induces allosteric changes in the N-lobe extension of the receiver kinase
leading to the conformational changes in its αC-helix and A-loop required to switch on the activated
state (Figure 4b). The intimation that brought to light this dimeric mechanism of kinase activation
was hidden in the original structure of the EGFR kinase bound with erlotinib [120], which in the
crystal lattice showed a sizeable interface between the N-lobe of one kinase domain and the C-lobe of
the other. The asymmetric dimer of kinase domains and its allosteric activation mechanism in trans
resembles the mechanism by which cyclin-dependent kinase is activated by cyclin, with the C-lobe
of the activator kinase domain playing the role of the cyclin. Notably, in the Src/CDK-like inactive
conformation the contact points in the hydrophobic surface on the N-lobe of the receiver kinase are
sequestered (reviewed in [174]), making them specific to the active conformation.
Normal functioning of the asymmetric kinase dimer requires kinase domains to cycle between
active and inactive states. Because of this cyclic nature, it has become increasingly clear that the function
of the receptor can only be understood by taking dynamic properties into account. MD simulations
played a leading role in this context. Within the kinase domain, a ‘block-based’ intermediate model
was proposed in which sparse clusters of closely interacting residues (e.g., motifs) can maintain
a weak association to other motifs and thus pass information between more distant regions of a
protein, thereby forming an allosteric network that can orchestrate cooperative protein motions and
transmit allosteric signals to distal sites [175]. Dixit and Verkhiver [176] used MD simulations to
test the possibility of long-range allosteric communication in the ABL and EGFR kinase monomers
and in the EGFR asymmetric kinase dimer. The results provided evidence for a dynamic network of
inter-communicating clusters of residues, involving the conserved conformationally adaptive αC-helix
in the N-lobe andαI andαF in the C-lobe, which may control long-range inter-domain coupling, thereby
allosterically regulating the activation of EGFR’s kinase. It was also found that the T766M gatekeeper
mutation enhances long-range communication among allosterically coupled motifs, resulting in the
stabilisation of the active kinase form.
Another example of structural cross-talk between the catalytic site and the asymmetric dimer
interface was provided by MD simulations carried out by Shan et al. [164]. These suggested that the
L834R mutation increases the order of the N-lobe surface in the monomer, thereby lowering the energetic
cost of asymmetric kinase dimerisation in the mutant EGFR compared with wild type. This mechanism
was subsequently validated by Red-Brewer et al. [156]. First, a crystal structure of the L834R/T766M
double mutant in the active conformation revealed an asymmetric dimer interface essentially identical
to that in wild type EGFR. Secondly, the lower energetic costs of kinase dimerisation provided by the
pre-ordering of the N-lobe of the mutant monomer are consistent with directional ‘super-acceptor
activity’, which is particularly prominent in the TKI-resistant L834R/T766M double mutant.
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4.3. Active and Inactive Kinase Dimers and Structural Cross-Talk with the TM, JM and C-Terminal
Tail Domains
Crucial vi ence for the involvement of the JM domain in th formatio of the symmetric
kinase dimer was provided by Jura et al. [177], who compared the asymmetric dimer structure of the
HER4 kinase [178], which included the JMB portion of the JM seg ent, with the asymmetric dimer
structure of EGFR, which did not. The realisation was that in the crystal lattice of the HER4 structure,
the JMB segment, provided by the receiver kinase domain, latches the two kinase domains together
by running along the surface of the C-lobe of the activator kinase, thereby reinforcing dimerisation.
Crucially, mutations in conserved C-lobe residues that anchor the JMB latch (e.g., Asn 972, Arg 949,
Asp 950, Arg 953 in the C-lobe) were found to inhibit EGFR autophosphorylation in cell-based assays
substantially. Coetaneous work by Red-Brewer et al. [179] revealed two crystal structures of the EGFR
kinase that extended from residue 645 to 998, thus including the entire inner JM region and some
40 residues of the C-terminus. In these, otherwise canonical, asymmetric EGFR kinase dimer structures
the contacts between the donor and receiver kinases include parts of the JM domain (Figure 5a). These
showed that, as predicted by Jura et al. [177], the C-terminal half of the JM of the receiver cradles
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the C-lobe of the activator, thereby stabilising the asymmetric dimer. Interestingly, this work also
established that the oncogenic activation of the L834R kinase was also regulated by the JM domain,
presumably by aiding further the stabilising effect of the L834R mutation on the asymmetric kinase
dimer, as was later shown by a combination of MD simulations, X-ray crystallography and cell-based
assays [156,164].
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Figure 5. Asymmetric and symmetric kinase dimers showing interactions with the juxtamembrane (JM)
and C-terminal domains. (a) Crystal structure of the EGFR kinase from residue 645 to 998, including
the entire inner JM region and some 40 residues of the C-terminus. The structure shows that the
C-terminal half of the JM of the receiver cradles the C-lobe of the activator, thereby stabilising the
asymmetric dimer. (1) shows the structure with an inactivating K721M mutation, closely resembling
the structure for EGFR lacking the JM region (2). (3) shows the detail of the side-chains in the acceptor
JM region (green), in contact with the C-lobe of the donor kinase domain. Taken, with permission, from
Red-Brewer et al. [179]. (b) Structure of the symmetric inactive dimer. (1) gives an overview of the
structure, while (2) shows the hydrophobic packing between the C-terminal AP-2 helix and the N-lobe
of monomers A and B, respectively. (3) shows the electrostatic hook that forms between the C-terminal
tail of EGFR and the hinge region of its kinase domain. Taken, with permission, from Jura et al. [177].
The crystal structure in Figure 5a still misses the majority of the C-terminal tail, which in human
EGFR spans ~230 residues (Gln958 to Ala1186) and accounts for ~20% of the receptor mass. This is
because the sequence of the tail, being inconsistent with regular secondary structure, is likely to be
unstructured and cannot be readily crystallised. Only the kinase proximal C-terminal tail segment
has been visualised in crystal structures. Examples include the Src/CDK-like inactive structures of
the wild type kinase domain [125] or with the V924R or I682Q mutations, which block the formation
of the asymmetric kinase dimer [177] and [180]. These structures display a symmetric arrangement
of two kinases interacting head-to-head by their N-lobes with a pseudo two-fold screw symmetry
(Figure 5b) in which the first portion of the C-terminal tail (Ser967-Met978) forms an α-helix known
as the AP2 helix because it also interacts with the AP2 clathrin adaptor upon phosphorylation of Tyr
974 [181]. In these symmetric structures, the C-terminal tail establishes three interactions with the
kinase, all of which are consistent with autoinhibition. In one, the AP2 helix of each kinase mediates the
formation of the symmetric interface by interacting with the N-lobe of the partner kinase. The region
following the AP2 helix (spanning residues 979–990) is termed the electrostatic hook and contains
several acidic residues that interact with the hinge region of the kinase domain. Residues 991–998 form
a β-strand that tracks the surface of the kinase domain in a manner that resembles the latch formed by
the JM segment preventing the formation of the JM latch that is necessary for activation. Interestingly,
long-range communication was impaired in the symmetric form of the kinase dimer [176].
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Further information on interactions between the kinase domain and the C-terminus was provided
by Gajiwala et al. [161], who revealed six crystal structures of monomeric L834R and L834R/T766-EGFR
mutants spanning residues 672–998, which include the kinase domain and part of the C-terminal tail
partially ordered. Supported by biochemical and biophysical data, the results showed conformational
states of mutant kinase domains and show that both type I and type II inhibitors can recognise the active
state of the kinase. Interestingly, the crystal-packing interactions for L834R/T766M kinase domain in
complex with the MIG6 inhibitor peptide provided a model for recognition of one of the C-terminal
autophosphorylation sites, Tyr-1016, which does not require the receptor to be in a fully activated
state. These structures showed an autophosphorylation site interacting with the highly conserved
is-Arg-Asp motif from the catalytic loop of the neighbouring molecule, which may be suggestive of the
potential mechanism of autophosphorylation in trans.
It should be noted, however, that the regulatory role played by the C-terminal tail is not yet
fully understood. The short helix that contains Tyr992 found in some inactive structures (e.g., [36]) is
observed slightly shifted in many active structures (reviewed in [122]). Furthermore, in the catalytically
competent asymmetric dimer, a steric clash between the JMB segments and the C-terminal tail suggest
that the inhibitory role of the C-terminal tail may only be relevant to the receiver half of the active
dimer [122]. What is apparent is that both the JM and C-terminal tail play crucial regulatory roles.
This is recapitulated by MD simulations carried out by Mustafa at al. [182], which suggested highly
correlated regulatory motions between the ATP-binding kinase core and the flexible JM and C-terminal
tail domains as the enzyme cycles between active and inactive states. These results suggest that
ATP and substrate binding is allosterically coordinated with kinase dimerisation via conformational
changes in the JM and the C-terminal tail. Specifically, this work suggested that residues 980–994 of
the C-terminal tail, which interacts with the N-lobe region of the kinase core, function as a ‘fulcrum’
for inter-lobe pivoting by interacting with the hinge regions of the kinase core.
4.4. Structural Coupling Across the Plasma Membrane in Ligand-Bound Active Dimers
The ligand-induced EGFR monomer-dimer transition includes aspects of a sequential model
in which a flexible link across the plasma membrane could in principle be sufficient to facilitate the
formation of the asymmetric kinase dimer [171]. Structural coupling across the plasma membrane
had to be invoked nevertheless to explain other EGFR signalling features, including why intracellular
domains, and/or residues, like Thr654, can influence extracellular ligand-binding properties, including
negative cooperativity [183], or why different ligands can elicit different signalling responses [9,184].
Results summarised below, demonstrated the presence of structural coupling in ligand-bound dimers.
First, the motif of hydrophobic residues (L655RRLL659) in EGFR’s JMA suggested an α-helical
structure [177], as previously indicated by an NMR structure of a micelle-bound peptide containing
the JM segment of EGFR [185]. Based on this, Jura et al. [177] considered models of parallel and
anti-parallel helical dimers of the JMA and carried out a mutational study that suggested that the
antiparallel dimer was energetically more favourable. Furthermore, the antiparallel JMA dimer could
be structurally coupled to an N-crossing dimer arrangement of the TM helices. This model was since
validated by NMR using a fragment of EGFR spanning the TM helix and the first 29 residues of the JM
segment (residues 618–673) reconstituted in lipid bicelles [186]. Noticeably, a near-full-length receptor
model could be built in which the N-terminal part of the N-crossing TM-dimer could be linked across
the lipid bilayer to the back-to-back dimer. This was the first model in which the ECM and ICM met
across the membrane, with the only obvious gap being the short outer JM segment (Figure 6a).
Endres et al. [186] used NMR to recapitulate the previous results from Jura et al. [177]. From these
results, they were able to firmly propose conformational coupling across the plasma membrane in the
ligand-bound active dimer. Such coupling indeed occurred via the formation of an N-crossing TM dimer
linked to an antiparallel JMA helix dimer, as previously proposed by Jura et al. [177]. Accompanying
long timescale simulations by Arkhipov et al. [67] validated these results in an impressive simulation
of the near-full-length dimer embedded in a POPC/POPS bilayer (Figure 6b). As discussed above
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(Figure 3c), the extracellular portion of the dimer was observed to adopt tilted orientations, on occasion
making contact with the membrane.
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Jura et al. [177]. (b,c) simulation of the near full-length active and inactive dimers, respectively.
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atomistic MD simulations. Taken, with permission, from Zanetti-Domingues et al. [50].
4.5. Structural Coupling Across the Plasma Membrane in Ligand-Free Inactive Dimers
Evidence for ligand-free dimers has accumulated over the years, but their role in the cell is not yet
completely understood [187–195]. Arkhipov et al. [67] assembled a complete version of an inactive
dimer that included the simulation generated for the ECM dimer in the absence of bound ligands.
In this the larger separation between the C-terminal regions of the two DIVs allowed the two ECMs
to be connected to their ICMs via a C-crossing TM dimer (Figure 6c). By controlling the polarization
properties and water permeability of the micelles into which EGFR TM domains are resuspended, NMR
experimentally revealed a weakly polar C-terminal crossing TM dimer [196]. In turn, coarse-grained
simulations involving metadynamics free energy calculations also independently validated the existence
of the C-crossing TM dimer [197].
The simulation of the near-full-length inactive EGFR dimer also included a bilayer embedded
JMA, connected by the extended JMB to the inactive symmetric kinase dimer, as previously shown
by crystallographic data [177] (Figure 5b). Subsequent multiscale MD simulations further revealed
that strong interactions between the basic residues in JMA and PIP2-containing lipid bilayers aid
stabilisation of JMA dimer away from the membrane, thereby promoting a conformation corresponding
to an asymmetric kinase domain [198]. Unlike the simulated active dimer (Figure 6b), in which
the active core and substrate binding site of the receiver face the cell, in the simulated ligand-free
inactive dimer the positively charged patches of the kinase subunits of the symmetric kinase dimer
were oriented facing the negatively charged lipid bilayer, which was observed to sequestered them,
occluding the substrate-binding sites (Figure 4c).
4.6. Autoinhibition Mechanisms in Ligand-Free Dimers
A comparison between the simulations in Figure 6b,c provides a plausible explanation for how
the ligand-free extended dimer can remain autoinhibited in the absence of bound ligand. These
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simulations suggested that dimer autoinhibition depends on conformational coupling across the
plasma membrane, proposing a model of activation by which, upon ligand binding, the TM domains
would rotate or twist on the plane of the cell membrane, evolving from a C-crossing dimer into an
N-crossing TM dimer. This would reorient the intracellular kinase domain dimer from a symmetric
inactive configuration into an asymmetric active form, the so call “rotation model” [199]. However,
while the intracellular shape of the simulated symmetric dimer was consistent with low-resolution TEM
pictures of the near-complete receptor [171], the extended ECM dimer conformation was incompatible
with the stalk-to-stalk, non-extended, kinase-mediated dimer suggested by TEM images of purified,
near-full-length EGFR [96]. Furthermore, the sizeable DIV–DIV separation in the one-liganded
extended dimer (Figure 3b) would preclude the formation of the N-crossing TM dimer, which is
obligatory to form the active asymmetric kinase dimer. This is inconsistent with results from cell-based
assays that showed that a single ligand is sufficient to form active EGFR dimers [200].
Other possible models of ligand-free dimers include those displayed in Figure 6d,e.
Zanetti-Domingues et al. [50] used a repertoire of high-resolution imaging methods, including
FLImP, FRET, and single particle tracking, and combined these with atomistic MD simulations to
investigate the nature of ligand-free inactive dimers on the cell surface. Contrary to the proposed role
of the symmetric kinase dimer in the autoinhibition of wild type EGFR and the TM dimer rotation
model of activation [199], the data from Zanetti-Domingues et al. [50] showed that kinase domains of
ligand-free, non-monomer wild type EGFR complexes do not interact. Only mutant kinase species bear
populations of kinase dimers. A dimer consistent with a ligand-free extended architecture (Figure 6c)
was found for L680N-EGFR, a mutant in which the symmetric kinase dimer was stabilised by their
inability to form the asymmetric moiety [36]. In turn, binding of type I TKI, removal of plasma
membrane cholesterol, both of which promote the asymmetric kinase dimer [96,201], induced across
the plasma membrane the formation of a stalk-to-stalk dimer (Figure 6e). Together, these results
suggested conformational coupling across the plasma membrane in ligand-free dimers on cells.
The L834R mutation, predicted by previous simulations to promote the formation of the asymmetric
kinase dimer [164], was also found to promote inside-out the stalk-to-stalk dimer architecture (Figure 6e),
thereby also consistent with conformational coupling across the plasma membrane. Interestingly
FLImP results for T766M-EGFR suggested that this mutant can form similar size populations of
both back-to-back extended (Figure 6c) and stalk-to-stalk non-extended dimers (Figure 6e). This
finding predicted that, if conformational coupling occurs, counterintuitively, T766M-EGFR, which
is constitutively active, should form a significant number of symmetric kinase dimers. To test this
prediction, MD simulations of the symmetric kinase dimer were carried out and the free-energy
landscapes from the parallel tempering metadynamics (PTmetaD) simulations of Sutto et al. [80] were
reanalysed and re-projected as a function of different variables for wild type EGFR and T766M-EGFR.
The results from the simulations confirmed the experimental prediction, and indicated that the T766M
mutation has a dual effect; on one hand destabilising the asymmetric kinase dimer, and on the other
stabilising the symmetric one [50]. In turn, single particle tracking experiments showed that the
asymmetric and symmetric kinase dimers co-exist in equilibrium at the plasma membrane under the
modulation of the C-terminal domain. These results are a further example of the power of combining
high-resolution experimental results from cells with atomistic MD simulations.
5. Ligand-Free and Ligand-Bound Multimeric EGFR Assemblies
The presence of ligand-bound and ligand-free higher order EGFR oligomers on the cell surface
has been anticipated for years, but the lack of methods with sufficient resolution has hindered progress
towards determining the oligomer architecture [202]. This is compounded by the challenge poised
to MD simulations in handling extremely large simulations involving several millions of atoms.
Towards understanding oligomer architecture, the Kuriyan lab combined a mutational study with the
quantitative properties of single-molecule imaging, which can report the number of receptor units in
individual cell surface receptor complexes [203], and molecular modelling to generate a model of a
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ligand-bound multimer [204]. In the resulting model (Figure 7a) the ligand-bound dimers are stacked
side-to-side, with a DIV leg from one dimer interacting with a DIV leg from the other. Because these
dimers are open structures, higher-order multimers can readily be formed by adding additional dimers
through the propagation of the DIV-DIV interaction.
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by connecting extracellular modules (PDB: 3NJP) to the structure of dim ric ansmembrane helices
(PDB: 2M20) d a chain of kinase domains (PDB: 2GS6 and 3GOP). Taken, with permission, from
Huang et al. [204]. (b) A structur l model for EGFR tetra ers derived from FLImP measurements
and MD simulation. The figure shows an illustration of an open-ended oligomerization scheme for
EGFR extracellular do ains based on repeating the back-to-back and face-to-face interactions. The two
structures below show the full-length tetramer model and the arrangement of the two intracellular
active kinase dimers in that model. The phosphorylation site Tyr992 (green) of one receptor is positioned
in the proximity of the active site (red) of its neighbour’s kinase domain. Taken, with permission, from
Needham et al. [49]. (c) A model of an open-ended oligomer 9G8-bound EGFR extracellular domains
in the inactive conformation. This was assembled from crystal contacts in PDB ID 4KRP42. 9G8-NB is
shown in cyan, EGFR DI in green, DII in red, DIII in blue, and DIV in grey. (d) A model dimer structure
of free EGFR extracellular domains and their TM domains in the lipid bilayer (based on a snapshot
of a simulation at 20 µs). In the left and middle panels, one of the two transmembrane helices can be
seen. On the right is shown the dimer seen from the membrane, highlighting the interaction between
DI and DII and between DIV and DIII. (e) The architecture of ligand-free head-to-head polymers,
showing a polymer chain formed by repeating the head-to-head interface, based on separations derived
from FLImP. The intensity is graded according to the abundance of the particular oligomer size.
(f) A ligand-free oligomer viewed from the front, showing the separation between non-interacting
ICM units predicted by extracellular head-to-head interactions. (c–f) taken, with permission, from
Zanetti-Domingues et al. [50].
Soon afterward, Needham et al. [49] reported a long-timescale atomic-resolution model of a near
full-length ligand-bound tetramer simulated using Anton-based methods. In this tetramer, back-to-back
dimers assemble oligomers via unoccupied ligand-binding sites, establishing a ‘face-to-face’ interaction
(Figure 7b). The model is also open-ended, growing by the lateral addition of back-to-back dimers joined
by face-to-face interfaces. Because the face-to-face interaction largely overlaps with the ligand-binding
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interface, the model implies that ligand binding and the face-to-face dimer interaction between
back-to-back dimers compete with one another. This may be an important factor contributing to the
negative cooperativity of EGFR ligand binding.
The 2D lateral separations between the receptors predicted by the above back-to-back/face-to-face
oligomer assembly were experimentally validated using FLImP data at 4.8 nm resolution by Needham
et al. [49], whilst FRET data was used to validate the predicted vertical separations between bound
ligands to the plasma membrane, which are different in dimers and oligomers. This is another example
of the opportunities provided by high-resolution data in being able to constrain atomic-resolution
structure when crystallographic data are not available, as it is the case for EGFR oligomers. This work
also showed that the role of these oligomers is to organise kinase-active dimers in ways optimal for
auto-phosphorylation (Figure 7b).
Ligand-free oligomers have also been frequently reported (e.g., [49,189,192,193]. To investigate
the nature of these oligomers, Zanetti-Domingues et al. [50] revealed a polymer chain architecture by
using a combination of high-resolution imaging methods and MD simulations. After the polymer
architecture was first hinted by the imaging, monomer crystal structures were searched to find lattice
contacts that might reveal previously unidentified oligomer interfaces consistent with this. A suitable
one was found in the monomer contacts of the tethered structure bound to the 9G8 nanobody [89]
(Figure 7c). Simulations carried out starting from the asymmetric dimer seen in the crystal packing
revealed a stable head-to-head dimer conformation (Figure 7d). This was akin to the crystal dimer
conformation in that it remains open-ended and asymmetric, maintaining the trans interaction between
the DIII of one monomer and the DIV of the other, but it additionally bears a trans interaction between
DI and DII. As previously found in the simulations of the ECM of EGFR [67], the tethered conformation
of the crystal structure was also consistently unstable. The DI and DIII in both monomers gained
stable cis interaction with one another, giving rise to a conformation similar to that in the back-to-back
inactive dimer in Figure 6c in terms of DI, DII, and DIII. The separations between DI and DIII to the
membrane predicted by the head-to-head dimer model were validated by FRET results. In turn, the
biological relevance of the ligand-free head-to-head dimer was suggested by the finding that the amino
acids involved in the head-to-head interface (6–238) are missing in the constitutively active variant
EGFRvIII prevalent in glioblastoma [205].
From the head-to-head dimer, higher order polymers of various lengths were assembled by
incorporating additional protomers and repeating the head-to-head interaction [50]. The resulting
polymer chain displays curvature in the plane of the membrane that arises because the DIII–DIII
separation between nearest neighbours is larger than DI–DI (illustrated in Figure 7e). The resulting
curvature is commensurate with the diameter around relevant plasma membrane vesicles [206].
Furthermore, single particle tracking showed that the kinase domains of head-to-head dimers and
oligomers do not interact (Figure 7f). Together, this work suggested that the role of the head-to-head
interaction is two-fold. On the one hand, it drives oligomer assembly, priming receptors for a quick
response to growth factor. On the other, it maintains TM helices sufficiently apart to oppose the
formation of kinase-mediated dimers. Indeed, the work also showed that kinase-mediated dimerisation
breaks the head-to-head interaction, suggesting the latter is important for autoinhibition.
6. Conclusions
In this review, we have brought together sources of structural information from different disciplines
regarding the atomistic structure of EGFR in its different oligomer forms and the presence and
absence of the ligand stimulus. While it remains indisputable that the depth of our understanding
of structure/function relationships is absolutely dependent on the availability of high-resolution
structures, the bulk of which in the EGFR field arises from X-ray protein crystallography, it is
also increasingly obvious that protein crystallography alone cannot provide crucial details on the
functioning of the receptor on the cell surface. This is precisely the environment where anti-cancer
drugs are bound to interact with the receptor. Among other challenges, the flexibility of EGFR
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compounded with its high degree of post-translational modifications, the two-dimensional constraints
imposed by the plasma membrane, and interactions between the receptor with other lipids and many
proteins, make a multi-disciplinary approach to structure determination a key factor on our success to
understand the biology of EGFR signalling. In light of the results reviewed here, we propose that MD
simulations are bound to play an increasingly important role in our understanding of EGFR signalling
and its dysregulation in oncogenic diseases. Uniquely, in a discipline that investigate mechanisms
underpinning the functioning of very complex systems, like biology, atomistic MD simulations can play
a unique predictive role, fulfilling, at least in part, the role theoretical principles play in other disciplines,
like in physics. To quote from Albert Einstein, in physics “A theory can be proved by experiment; but
no path leads from experiment to the birth of a theory”. The development of ever-increasing resolution
multi-disciplinary approaches, crucially in cells, in parallel with more powerful MD simulations will be
paramount in unleashing the potential of a combined theoretical and experimental approach in biology.
The combination of theory and experiments has already shed much light on the mechanisms
by which NSCLC mutations dysregulate the EGFR and modulate its sensitivity and resistance to
TKIs. These mutations allow the enzyme to escape the quiescent intrinsically disordered states and
increase its time of residence in the catalytically activated state, by facilitating dimerisation of the
enzyme (e.g., [80,156,161,164]). Taken the above results together, dysregulated EGFR mutant enzymes
may drive NSCLC via changes in their dynamic nature. The greater propensity to form asymmetric
dimers is a ‘game changer’ in the ligand-free state, bringing about the formation of constitutively
active kinase-mediated dimers that can bypass the autoinhibition provided in the absence of ligand by
extracellular interactions [50], thereby increasing the activity further.
The ability of cell surface receptors to form higher order oligomers has been hailed as a new
paradigm in signal transduction [207]. The nature of higher order assemblies must be understood
in detail because their presence can explain functional features that cannot be accounted in the
context of dimers, like, for example, threshold behaviour, signal amplification and biological noise
reduction [208,209]. However, the overall role of oligomerisation in signal transduction, and the
mechanisms driving oligomer formation have not yet been resolved. Delineating an in cellulo structural
‘solution’ to these properties exploiting somatic mutations and novel approaches will profoundly impact
our understanding of growth factor receptor signalling via higher-order assemblies and guide novel
opportunities for therapeutic intervention. The combination of MD simulations with super-resolution
methods like FLImP, single particle imaging and tracking, and FRET is beginning to make substantive
inroads towards this goal.
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